NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 294 filers reported holding NEKTAR THERAPEUTICS in Q3 2019. The put-call ratio across all filers is 0.81 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $827,000 | +4.8% | 46,067 | +0.2% | 0.01% | 0.0% |
| Q2 2021 | $789,000 | -41.5% | 45,967 | -31.9% | 0.01% | -44.4% |
| Q1 2021 | $1,349,000 | +21.4% | 67,467 | +3.2% | 0.01% | +12.5% |
| Q4 2020 | $1,111,000 | +2.8% | 65,367 | +0.3% | 0.01% | -11.1% |
| Q3 2020 | $1,081,000 | -27.9% | 65,167 | +0.6% | 0.01% | -30.8% |
| Q2 2020 | $1,500,000 | +72.2% | 64,767 | +32.7% | 0.01% | +30.0% |
| Q1 2020 | $871,000 | -22.1% | 48,800 | -5.8% | 0.01% | +11.1% |
| Q4 2019 | $1,118,000 | +45.8% | 51,800 | +23.0% | 0.01% | +28.6% |
| Q3 2019 | $767,000 | -48.3% | 42,100 | +1.0% | 0.01% | -46.2% |
| Q2 2019 | $1,484,000 | -12.0% | 41,700 | -16.9% | 0.01% | -7.1% |
| Q1 2019 | $1,687,000 | +3.5% | 50,200 | +1.2% | 0.01% | -6.7% |
| Q4 2018 | $1,630,000 | -48.0% | 49,600 | -3.5% | 0.02% | -34.8% |
| Q3 2018 | $3,133,000 | +34.5% | 51,400 | +7.8% | 0.02% | +27.8% |
| Q2 2018 | $2,329,000 | -53.8% | 47,700 | +0.6% | 0.02% | -56.1% |
| Q1 2018 | $5,037,000 | – | 47,400 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TIRSCHWELL & LOEWY INC | 588,908 | $7,138,000 | 1.23% |
| Granahan Investment Management | 3,693,956 | $44,771,000 | 1.21% |
| NEA Management Company, LLC | 1,825,600 | $22,126,000 | 1.09% |
| FIC CAPITAL INC | 150,868 | $1,829,000 | 0.75% |
| Rhenman & Partners Asset Management AB | 181,797 | $2,203,000 | 0.66% |
| SOPHROSYNE CAPITAL LLC | 60,200 | $728,000 | 0.64% |
| HARVEY CAPITAL MANAGEMENT INC | 130,400 | $1,580,000 | 0.63% |
| Artal Group S.A. | 1,300,000 | $15,756,000 | 0.57% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 564,418 | $6,840,000 | 0.47% |
| OppenheimerFunds, Inc. | 24,400,000 | $295,728,000 | 0.35% |